Eli Lilly to Sell Baqsimi Product to Amphastar
By Colin Kellaher
Eli Lilly & Co. on Monday said it agreed to sell its Baqsimi hypoglycemia treatment to Amphastar Pharmaceuticals Inc. in a deal potentially worth more than $1 billion.
Indianapolis drugmaker Eli Lilly said it would receive $500 million in cash at closing, slated for the second or third quarter, along with another $125 million in cash upon the one-year anniversary of closing.
Eli Lilly said it is also eligible for up to $450 million in sales-based milestone payments related to Baqsimi, a nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes that generated sales of $139.3 million in 2022.
Eli Lilly said the sale will help it focus on advancing its pipeline of potential breakthrough treatments, while Amphastar will provide a dedicated commercial investment for Baqsimi.
Amphastar, a Rancho Cucamonga, Calif., biopharmaceutical company that focuses primarily on injectable, inhalation and intranasal products, posted 2022 net revenue of $499 million.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 24, 2023 07:27 ET (11:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact